Literature DB >> 25949041

A case report of bittern intoxication.

Hyun Min Jung1, Jin Hui Paik1, Ji Hye Kim1, Seung Baik Han1.   

Abstract

Bittern is made from marine water after extraction of salt, and its major components include magnesium chloride, magnesium sulfate, potassium chloride, sodium chloride and magnesium bromide. For a long time, it has been used as the main ingredient of tofu coagulant and chemical weapons. A 73-year-old woman arrived to the emergency department after a suicide attempt by drinking an unknown amount bittern. She complained of dizziness, general weakness, and altered mental state (Glasgow Coma Scale (GCS) 13/15). The brain computed tomography (CT) and magnetic resonance imaging (MRI) showed no abnormality. But blood chemistry showed hypermagnesemia ([Mg(2+)] 7.8 mEq/L) and hypernatremia ([Na(+)] 149 mEq/L). Electrocardiograph showed QT prolongation of 0.482 s. Electrolyte imbalances were corrected following adequate fluid therapy and injection of calcium gluconate. The patient recovered/was subsequently discharged without any complications. Electrolyte imbalances are a common presentation following bittern poisoning. Severe side effects like respiratory depression, hypotension, arrhythmia, bradycardia, and cardiac arrest can also occur. Patients will require immediate fluid therapy and correction of electrolyte imbalances. The symptoms vary depending on the electrolyte levels. It is mandatory to closely monitor the electrolyte levels and electrocardiograph in these patients.

Entities:  

Keywords:  Complications; hypermagnesemia; poisoning

Year:  2015        PMID: 25949041      PMCID: PMC4411570          DOI: 10.4103/0974-2700.145426

Source DB:  PubMed          Journal:  J Emerg Trauma Shock        ISSN: 0974-2700


INTRODUCTION

Bittern is made from marine water after extraction of salts, and its gravity is 1.3. Its major components include magnesium chloride, magnesium sulfate, potassium chloride, sodium chloride, and magnesium bromide. Bittern has long been used as a main ingredient for tofu coagulant and chemical weapons. Currently, the industrial bittern is used more prevalently than the natural one. Bittern contains various amounts of electrolyte components such as sodium and magnesium. Excess consumption may lead to electrolyte imbalances. We report a case of suicidal intake of bittern and its toxic symptoms with review from literatures.

CASE REPORT

A 73-year-old woman arrived to the emergency department after an attempt suicide by taking five zolpidem pills and bittern of unknown amounts. She complained of dizziness and general weakness. There was no other past history other than hypertension. Her GCS was 13/15(E3/V4/M6). The patient was oriented to time, place and person and normal muscle power and sensory in the extremities. Her initial blood pressure was 149/94 mmHg, pulse rate 82 beats/min, respiratory rate 28 breaths/min and body temperature 36.0 °C. Electrocardiograph showed QT prolongation of 0.482 s [Figure 1].
Figure 1

Electrocardiograph shows QT interval prolongation

Electrocardiograph shows QT interval prolongation Complete blood counts showed white blood cell (WBC) counts 1,249/mL, hemoglobin (Hb) 16.9 g/dL and platelet counts 265,000/mL. In addition, the arterial blood gas analysis (ABGA) showed pH 7.36, PCO2 35.0 mmHg, PO2 68.6 mmHg, HCO32− 19.2 mmol/L, O2 saturation 92.4%, glucose 145 mg/dL, blood urea nitrogen (BUN) 13.6 mg/dL, creatinine 0.77 mg/dL, aspartate aminotransferase (AST) 49 IU/L, alanine aminotransferase (ALT) 27 IU/L, albumin 5.5 g/dL, C-reactive protein (CRP) 0.09 mg/dL, [Na+] 149 mEq/L, [K+] 4.5 mEq/L, [Cl−] 120 mEq/L and [Mg2+] 7.8 mEq/L. Zolpidem was measured as 0.12 mg/L on urinalysis and 0.94 mg/L on serum biochemistry. Brain CT taken right after the visit revealed no evidences of acute brain hemorrhage and following MRI showed no evidences of acute infarction. Altered mentality of patient might have been due to zolpidem (0.94 mg/L) ingestion. The patient also had electrolyte imbalance. Hypernatremia and hyperchloremia were corrected by infusion of half-saline and hypermagnesemia was corrected by injection of 10% calcium gluconate 20 mL. A repeat blood test 12 h later showed decreasing levels of [Na+], [K+], [Cl−], and [Mg2+] to 144, 4.3, 120, and 3.2 mEq/L, respectively. The mental status of patient returned to normal without any sequelae. Following further improvement of the electrolyte measurements, the patient was transferred to the general ward for conservative treatment. All electrolyte measurements returned to normal 4 days after the incident ([Na+] 138 mEq/L, [K+] 3.8 mEq/L, [Cl−] 109 mEq/L, and [Mg2+] 2.4 mEq/L). Electrocardiograph returned to normal after correcting electrolyte imbalances. The patient was transferred to the psychiatric ward for further evaluation and management of suicide attempt. The patient was discharged home 1 week after the incident.

DISCUSSION

The normal content of Mg2+ in the body is approximately 22.6 g and 50-60% is located in the bone.[1] It is one of the major intracellular divalent cations that are mostly found in the intracellular space. The normal recommended daily intake of Mg2+ is approximately 420 mg/day in adult men and 320 mg/day in adult women. The normal range of serum Mg2+ is between 1.7 and 2.3 mg/dL (0.75-0.95 mmol/L) with 80% being filtered in the glomerulus but only 3% is excreted in the urine.[1] Mg2+ metabolic derangement is associated with diabetes mellitus, chronic renal failure, nephrolithiasis, osteoporosis, aplastic osteopathy, and cardiovascular diseases.[2] Hypermagnesemia commonly occurs as a result of the overdosing of magnesium salts or magnesium-containing drugs; this is notable in patients with renal function insufficiency. The clinical presentation of magnesium poisoning depends on the magnesium serum concentration. A level of 5-8 mEq/L may result in nausea, flushing, headache, hyporeflexia, and lethargy. A level of 9-12 mEq/L may result in somnolence; loss of deep tendon reflexes; prolongation of QRS, PR, and QT intervals; bradycardia; and hypotension. A level above 15 mEq/L may result in complete heart block, respiratory paralysis, coma and shock. Asystole leading to death may occur in patients with [Mg2+] of >20 mEq/L.[3456] Following a comprehensive history taking and serum biochemistry, patients with bittern poisoning should receive adequate fluid infusion and correction of electrolyte imbalances. Magnesium derangement should also be corrected with injections of calcium gluconate. Diuretics or dialysis are recommended for patients with renal failure. As evident in the case reported, early diagnosis and treatment is essential for improvement of the patient's condition. It is mandatory to serially monitor the electrolyte levels and electrocardiograph to prevent more serious complications such as respiratory paralysis, coma, shock, or death.
  6 in total

1.  Hypermagnesemia-induced fatality following epsom salt gargles(1).

Authors:  Richard B Birrer; Anthony J Shallash; Vicken Totten
Journal:  J Emerg Med       Date:  2002-02       Impact factor: 1.484

2.  Iatrogenic magnesium overdose: two case reports.

Authors:  R J Vissers; R Purssell
Journal:  J Emerg Med       Date:  1996 Mar-Apr       Impact factor: 1.484

3.  Hypermagnesemia induced by massive cathartic ingestion in an elderly woman without pre-existing renal dysfunction.

Authors:  Makoto Kontani; Akinori Hara; Shinji Ohta; Takayuki Ikeda
Journal:  Intern Med       Date:  2005-05       Impact factor: 1.271

Review 4.  Hypermagnesemia-induced cardiopulmonary arrest before induction of anesthesia for emergency cesarean section.

Authors:  H Morisaki; S Yamamoto; Y Morita; Y Kotake; R Ochiai; J Takeda
Journal:  J Clin Anesth       Date:  2000-05       Impact factor: 9.452

Review 5.  Magnesium metabolism in health and disease.

Authors:  Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2009-03-10       Impact factor: 2.370

6.  Severe hypermagnesemia presenting with abnormal electrocardiographic findings similar to those of hyperkalemia in a child undergoing peritoneal dialysis.

Authors:  Won Kyoung Jhang; Yoon Jung Lee; Young A Kim; Seong Jong Park; Young Seo Park
Journal:  Korean J Pediatr       Date:  2013-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.